forgot link :
CytRx (CYTR) Soars on 2-Day Rally
BY Keris Alison Lahiff | 12/12/13 - 05:31 PM
A rally was sparked after the oncological specialist announced the success of a mid-stage clinical trial of its cancer treatment before the bell Wednesday. The aldoxorubicin study, an experimental treatment targeting soft-tissue sarcomas, was found to have an 80% to 100% success rate in progression-free survival over using chemotherapeutic agent doxorubicin in isolation.
The success of CytRx is in stark contrast to ImmunoCellular Therapeutics (IMUC_) which more than halved its value on Thursday. The cancer immunotherapy researcher closed 59.9% lower to $1.09, after a phase IIstudy of its cell-based vaccine treating aggressive brain tumors failed to reap statistical significance in overall survival among patients